Eupraxia PharmaceuticalsEPRX
About: Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
Employees: 33
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
24% more capital invested
Capital invested by funds: $4.55M [Q3] → $5.63M (+$1.09M) [Q4]
13% more funds holding
Funds holding: 8 [Q3] → 9 (+1) [Q4]
0.08% more ownership
Funds ownership: 5.05% [Q3] → 5.13% (+0.08%) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for EPRX.
Financial journalist opinion









